Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
Total Valuation
MoonLake Immunotherapeutics has a market cap or net worth of $3.41B. The enterprise value is $2.96B.
Market Cap$3.41B
Enterprise Value$2.96B
Share Statistics
MoonLake Immunotherapeutics has 63,474,255 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63,474,255
Owned by Insiders41.86%
Owned by Institutions0.21%
Financial Efficiency
MoonLake Immunotherapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -31.39%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-31.39%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count100
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio7.71
Price to Fair Value7.62
Price to FCF-22.51
Price to Operating Cash Flow-22.48
PEG Ratio1.00
Income Statement
In the last 12 months, MoonLake Immunotherapeutics had revenue of 0.00 and earned -120.68M in profits. Earnings per share was -1.92K.
Revenue0.00
Gross Profit0.00
Operating Income-143.09M
Pretax Income-120.96M
Net Income-120.68M
EBITDA-119.58M
Earnings Per Share (EPS)-1.92K
Cash Flow
In the last 12 months, operating cash flow was -139.78M and capital expenditures -342.75K, giving a free cash flow of -140.12M billion.
Operating Cash Flow-139.78M
Free Cash Flow-140.12M
Free Cash Flow per Share-2.21
Dividends & Yields
MoonLake Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.99
52-Week Price Change19.84%
50-Day Moving Average44.63
200-Day Moving Average45.38
Relative Strength Index (RSI)68.35
Average Volume (3m)464.51K
Important Dates
MoonLake Immunotherapeutics upcoming earnings date is Aug 7, 2025, Before Open (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
MoonLake Immunotherapeutics as a current ratio of 21.11, with Debt / Equity ratio of 18.55%
Current Ratio21.11
Quick Ratio21.11
Debt to Market Cap0.00
Net Debt to EBITDA1.49
Interest Coverage Ratio0.00
Taxes
In the past 12 months, MoonLake Immunotherapeutics has paid 282.20K in taxes.
Income Tax282.20K
Effective Tax Rate>-0.01
Enterprise Valuation
MoonLake Immunotherapeutics EV to EBITDA ratio is -26.99, with an EV/FCF ratio of -27.55.
EV to Sales0.00
EV to EBITDA-26.99
EV to Free Cash Flow-27.55
EV to Operating Cash Flow-27.68
Balance Sheet
MoonLake Immunotherapeutics has $480.13M in cash and marketable securities with $75.60M in debt, giving a net cash position of -$404.53M billion.
Cash & Marketable Securities$480.13M
Total Debt$75.60M
Net Cash-$404.53M
Net Cash Per Share-$6.37
Tangible Book Value Per Share$7.21
Margins
Gross margin is 22.40%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin22.40%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MoonLake Immunotherapeutics is $75.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$75.90
Price Target Upside41.68% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast-147.80%